Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$9.25
+0.8%
$6.05
$1.86
$10.29
$23.98M0.863,824 shs33,403 shs
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$5.30
-2.2%
$5.90
$2.68
$8.22
$166.97M4.06296,074 shs233,835 shs
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$2.31
-3.8%
$13.23
$4.50
$27.32
$3.32M2.0778,851 shs193,916 shs
Reliv' International, Inc. stock logo
RELV
Reliv' International
$5.94
$3.51
$2.50
$4.42
$10.37M-0.123,200 shs4,727 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
+6.25%+3.49%+55.56%+222.11%+134.99%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
+0.93%+3.44%-17.88%+38.62%+32.84%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-1.64%+4.35%+44.58%+42.01%-15.79%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+54.29%+63.19%+51.15%+61.63%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.847 of 5 stars
3.52.00.00.03.80.80.0
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
1.2983 of 5 stars
3.50.00.00.03.00.80.6
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.00
Buy$16.0072.97% Upside
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
3.00
Buy$24.00352.83% Upside
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A

Current Analyst Ratings

Latest CAPR, RELV, BNTC, and NVUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
4/22/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
3/1/2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
2/15/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$61K393.05N/AN/A$0.12 per share77.08
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$25.18M6.63N/AN/A$0.73 per share7.26
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.30$0.13 per share44.53$6.36 per share0.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$19.56M-$1.75N/AN/AN/A-204.34%-142.81%5/20/2024 (Estimated)
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$22.29M-$0.87N/A44.17N/A-88.52%-299.67%-45.54%5/13/2024 (Confirmed)
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A

Latest CAPR, RELV, BNTC, and NVUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.11N/A+$0.11N/AN/AN/A  
2/29/2024Q4 2023
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.23-$0.02+$0.21-$0.02$5.80 million$12.09 million
2/13/2024Q2 2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A-$2.64-$2.64-$2.64N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
0.01
3.62
3.62
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A
1.63
1.63
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
52.19%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
21.68%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%

Insider Ownership

CompanyInsider Ownership
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
4.30%
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
12.00%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
2.20%
Reliv' International, Inc. stock logo
RELV
Reliv' International
31.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
162.59 million2.48 millionNo Data
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A31.50 million27.72 millionOptionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable

CAPR, RELV, BNTC, and NVUS Headlines

SourceHeadline
Agape ATP Corporation (ATPC)Agape ATP Corporation (ATPC)
finance.yahoo.com - April 18 at 12:43 AM
North American Morning Briefing: Stocks Set for -2-North American Morning Briefing: Stocks Set for -2-
morningstar.com - March 29 at 11:28 AM
India and Armenia: Emerging Geostrategic SynergyIndia and Armenia: Emerging Geostrategic Synergy
asbarez.com - March 4 at 5:30 PM
Shikhar Dhawan turns 38: Reliving the career highlights of Indian teams GabbarShikhar Dhawan turns 38: Reliving the career highlights of Indian team's 'Gabbar'
news.webindia123.com - December 5 at 3:41 PM
Reliv Celebrates 35 Years of Nourishing the World and Introduces New Healthy Aging SystemsReliv Celebrates 35 Years of Nourishing the World and Introduces New Healthy Aging Systems
finance.yahoo.com - October 10 at 10:31 AM
Reliance Naval and Engineering LtdReliance Naval and Engineering Ltd
reuters.com - September 16 at 12:17 PM
RELV Real-Time QuotesRELV Real-Time Quotes
nasdaq.com - January 21 at 7:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma logo

Benitec Biopharma

NASDAQ:BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Capricor Therapeutics logo

Capricor Therapeutics

NASDAQ:CAPR
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Novus Therapeutics logo

Novus Therapeutics

NASDAQ:NVUS
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.